Growth plate senescence, chondrocyte biology, and the growth hormone–insulin-like growth factor 1 axis in childhood growth
- 5 October 2026
- journal article
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
Abstract
Longitudinal bone growth in children depends on endochondral ossification within the epiphyseal growth plate, a process long viewed as a passive readout of systemic hormones but now recognized as an actively regulated, self-limiting process. This mini-review synthesizes recent evidence on chondrocyte biology, growth plate senescence, and the growth hormone (GH)–insulin-like growth factor 1 (IGF-1) axis. Local paracrine networks establish precise antagonistic and synergistic interactions: fibroblast growth factor receptor 3 (FGFR3) suppresses chondrocyte proliferation via MAPK/STAT signaling, while the C-type natriuretic peptide/NPR2 pathway counters this via cGMP-mediated stimulation; the Indian hedgehog–parathyroid hormone–related protein feedback loop, the SHOX gene, and mechanical loading provide additional structural control. Growth plate senescence follows a proposed localized, cell-counting mechanism reflecting cumulative chondrocyte division that current evidence supports but that has not been established as the sole explanation for chronological variation in physeal closure. Estrogen is a key accelerant of this senescent process during puberty. Pathogenic variants in these local regulators underlie conditions such as achondroplasia and a minority of cases classified as idiopathic short stature, and mechanism-targeted therapies – including vosoritide, a C-type natriuretic peptide analog, together with the FGFR3-directed tyrosine kinase inhibitor infigratinib and the once-weekly CNP prodrug navepegritide – illustrate, for achondroplasia specifically, how targeting a defined paracrine lesion can produce growth responses that systemic hormone stimulation alone does not achieve in that disorder. For a limited group of monogenic growth-plate disorders, resolving these molecular networks is beginning to complement uniform systemic intervention with precision, mechanism-based therapy, although this paradigm remains investigational for the great majority of children with short stature.Keywords
This publication has 19 references indexed in Scilit:
- Oral Infigratinib Therapy in Children with AchondroplasiaNew England Journal of Medicine, 2025
- Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trialeClinicalMedicine, 2023
- Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trialThe Lancet, 2020
- C-Type Natriuretic Peptide Analogue Therapy in Children with AchondroplasiaNew England Journal of Medicine, 2019
- Achondroplasia: Development, pathogenesis, and therapyDevelopmental Dynamics, 2016
- Mechanisms of Growth Plate Maturation and Epiphyseal FusionHormone Research in Paediatrics, 2011
- Fundamental limits on longitudinal bone growth: growth plate senescence and epiphyseal fusionTrends in Endocrinology & Metabolism, 2004
- Developmental regulation of the growth plateNature, 2003
- Effects of estrogen on growth plate senescence and epiphyseal fusionProceedings of the National Academy of Sciences, 2001
- Bone “mass” and the “mechanostat”: A proposalThe Anatomical Record, 1987